All Updates

All Updates

icon
Filter
Management news
Alumis files for IPO to fund Phase III trials of plaque psoriasis drug candidate 'ESK-001'
Precision Medicine
Jun 10, 2024
This week:
Funding
Brightpick raises USD 12 million in funding to accelerate US deployment
Logistics Tech
Today
Partnerships
ArcelorMittal partners with HP to develop steel additive manufacturing solutions
Additive Manufacturing
Today
Product updates
Synspective commences full-scale SAR satellite manufacturing at Yamato Technology Center
Next-gen Satellites
Today
Product updates
IDEAYA Biosciences presents new development candidate IDE034
Precision Medicine
Yesterday
Management news
23andMe lays off 40% of workforce; discontinues therapeutics development division
Precision Medicine
Yesterday
Partnerships
EHang partners with Enpower to enhance electric motor systems for eVTOL aircraft
Passenger eVTOL Aircraft
Yesterday
Funding
Nerai Bio raises ~USD 171,000 in venture funding to develop gene editing candidates
Human Gene Editing
Yesterday
Funding
Aridditive raises EUR 500,000 in pre-seed funding
Additive Manufacturing
Yesterday
Industry news
Japan launches world's first wooden satellite
Next-gen Satellites
Yesterday
Partnerships
Maxar Intelligence expands partnership with HERE Technologies to scale automated mapmaking
Next-gen Satellites
Yesterday
Precision Medicine

Precision Medicine

Jun 10, 2024

Alumis files for IPO to fund Phase III trials of plaque psoriasis drug candidate 'ESK-001'

Management news

  • Alumis has filed for an IPO to fund Phase III trials of ESK-001, a drug targeting plaque psoriasis and other conditions.

  • The trials are set to begin in late 2024, with results expected in 2026. The company aims to position ESK-001 as a competitor to Bristol Myers Squibb's Sotyktu and Takeda's TAK-279, focusing on its potential in treating autoimmune diseases.

  • The proceeds from the IPO are also aimed at raising funds to support the development of another drug, A-005, for neurological diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.